Human growth hormone plays an important role in human growth processes and metabolism processes. HGH is secreted in bursts by the anterior part of the pituitary gland. HGH levels are determined by this secretion and HGH levels affect the growth of an individual. A normal amount of HGH is required in every individual to optimize his chances for growth development. However, not all people are fortunate to have the exact amount of HGH. The incapacity to have normal HGH levels lead to HGH diseases. These diseases are characterized by low stature or excessive height.
The treatment and cure for these HGH diseases has been the subject of research for a long period of time. Human growth hormone was discovered by Dr. Harvey Cushing in 1912. The HGH was widely discussed and explained all over scientific journals in the next ten years. In 1958, Dr. Maurice Maben successfully treated a 17 year old boy of growth hormone deficiency. Maben purified growth hormone from a cadaver and injected it to the boy to enhance the deficiency. Because of Maben’s successful treatment, researchers extensively looked at all possibilities of treating HGH diseases. Cadaver GH became a popular method in treating HGH diseases.
The method of using cadaver GH for treating HGH diseases was decreased when majority of the patients treated with it was diagnosed with Creutzfeldt-Jakob disease (CJD) in 1985 – a very rare neurodegenerative disease that is transmissible and usually ends in death within eight months of acquiring the disease. CJD was given large attention because it had appeared as a side effect of cadaver GH.